ライフサイエンスコーパス: reoperation

1 ence of hiatal hernia or wrap migration, and reoperation.

2 jection were associated with higher rates of reoperation.

3 -in-valve [ViV]) may offer an advantage over reoperation.

4 strabismus procedures, 851 (7.7%) underwent reoperation.

5 aken into consideration when counselling for reoperation.

6 ator, sepsis, septic shock, readmission, and reoperation.

7 were readily resolved with subsequent early reoperation.

8 patients with failed initial surgery undergo reoperation.

9 none of these significantly grew or required reoperation.

10 centers have lower rates of complication and reoperation.

11 fully assess lifetime risks, particularly of reoperation.

12 lmonary, infectious, hematologic, renal, and reoperation.

13 tive mortality, severe complications, and/or reoperation.

14 Weight loss is maintained after reoperation.

15 n, and weight in patients who did not have a reoperation.

16 tenosis and aortic regurgitation, as well as reoperation.

17 ents (4.7%) underwent a gastric band-related reoperation.

18 is recommended as first-line imaging before reoperation.

19 90-day mortality, serious complications, and reoperation.

20 cting adverse events including mortality and reoperation.

21 eater than 32, combined transplantation, and reoperation.

22 l complications were reported except for one reoperation.

23 s was associated with a 33% lower risk for a reoperation.

24 mus surgeries, but the accuracy decreases in reoperations.

25 f serious infection-related complications or reoperations.

26 with the patient and often require multiple reoperations.

27 r malfunction), driven by a reduced need for reoperations.

28 224 million (47.6%) of the payments were for reoperations.

29 success), interventions, complications, and reoperations.

30 s for the index operation and any subsequent reoperations.

31 demonstrated less pump thrombosis requiring reoperation (0 versus 36 points, P<0.001) or medically m

32 = 0.34) or bleeding complications requiring reoperation (0.5% vs 1.6%; P = 0.62).

33 vs 2.5%; RR, 0.92 [95% CI, 0.84-1.00]), and reoperation (0.83% vs 0.96%; RR, 1.00 [95% CI, 0.86-1.17

34 nrollment; RR, 0.96 [95% CI, 0.91 to 1.00]), reoperations (0.49% after enrollment vs 0.45% before enr

35 al admission (11.6%), readmission (6.3%), or reoperation (1.1%).

36 Eighty patients required at least 1 reoperation (1.8% per patient-year).

37 ients with teres ligament patch, the rate of reoperations (1.3% vs 13.0%; P = 0.009), and also the ra

38 pital volume, as described by the equation % reoperation = 100/(total hospital case volume).

39 orbidity (18.7% vs 25.3%; P = 0.83), rate of reoperation (16.6% vs 21.0%; P = 0.22), length of hospit

40 ctions (6%-47%), readmissions (38%-74%), and reoperations (2%-15%) occurred.

41 complications (18% versus 24%, P=0.439), or reoperation (21% versus 24%, P=0.650).

42 sted rates of DSM (9.0% vs 7.1%; P < 0.001), reoperation (3.6% vs 2.7%; P < 0.001), and readmission (

43 in fatal bleeding (0% vs. 0.3%) or need for reoperation (4.7% vs. 4.6%).

44 After reoperation 46 patients (69.7%) were completely seizure-

45 A total of 725 patients (17.6%) underwent a reoperation: 593 were reexcisions (14.4%) and 132 were m

46 Overall, 526 of 6178 surgical patients had a reoperation (8.5%).

47 n with IBC (454 of 3391 [13.4%]) underwent a reoperation (adjusted odds ratio, 3.82; 95% CI, 3.19-4.5

48 If surgery has failed reoperation after careful re-evaluation may be a reasona

49 Reoperation after failed resective epilepsy surgery led

50 l improvements in survival and reductions in reoperations after CHD surgery were seen.

51 The number of reoperations after gastric banding is rapidly increasing

52 90-day mortality, serious complications, and reoperation (all P < 0.0001).

53 omplex defects, 5-year cumulative freedom of reoperation among patients operated on in 1990 to 1999 v

54 ow-up, 4636 patients (18.5%) underwent 17539 reoperations (an average of 3.8 procedures/patient).

55 Age under 2 years was associated with higher reoperation and abnormal binocularity rates (P < .001).

56 n and the number of lymph node metastases at reoperation and biochemical cure was strong after previo

57 discovered gallbladder cancer who underwent reoperation and had available data on the date of their

58 l-cause mortality with secondary outcomes of reoperation and infection.

59 e peeling was associated with lower rates of reoperation and RD.

60 appropriate and offer favorable freedom from reoperation and survival compared with mechanical valves

61 ught to examine recurrent MR risk along with reoperation and survival rates.

62 he incremental serum calcitonin level before reoperation and the number of lymph node metastases at r

63 All reoperations and 85% of readmissions were related to WLS

64 ge is to find methods to reduce the need for reoperations and further reduce long-term mortality.

65 Reoperations and hospital readmissions were adjudicated

66 as also associated with reduced incidence of reoperations and valve-related complications.

67 Risk factor prevalence (except reoperation) and expected mortality rates were generally

68 lity rate was 18.7% after stroke, 9.0% after reoperation, and 13.2% after major bleeding.

69 cidence of end-organ dysfunction, mortality, reoperation, and hospital readmission, with estimated po

70 percutaneous drainage procedures, unplanned reoperation, and hospital revisits).

71 All-cause mortality, stroke, reoperation, and major bleeding events.

72 e mortality; secondary outcomes were stroke, reoperation, and major bleeding.

73 e cholangiopancreatography, wound infection, reoperation, and mortality.

74 es of severe complication, any complication, reoperation, and percutaneous drainage (all P < 0.05).

75 nic Health Evaluation II (APACHE II) scores, reoperation, and postoperative bleeding.

76 omes included 30-day rates of complications, reoperation, and readmission in urgent cases compared wi

77 lure and a length of stay >75th percentile), reoperation, and readmission within 30 days.

78 y mitral repair rates, but also freedom from reoperation, and survival.

79 death or serious morbidity (DSM), unplanned reoperation, and unplanned readmission in concurrent ver

80 DP is associated with less reinterventions, reoperations, and need for readmission.

81 l measures, including serious complications, reoperations, and readmissions; hospital and surgeon vol

82 yses of the rate of recurrent infections and reoperations, and time trends in surgical treatment.

83 rt failure, paraplegia, dyspnea at rest, and reoperation are associated with the highest risk of post

84 ) were discovered incidentally and underwent reoperation at 3 different time intervals from the date

85 ersus 985 (33.8%) patients needed at least 1 reoperation before 16 years of age.

86 Patients who underwent reoperation between 4 and 8 weeks had the longest median

87 , but no difference was found in the type of reoperation between patients with DCIS and those with IB

88 ing and (2) study trends in the frequency of reoperations between 2005 and 2008 for patients who had

89 etic valve group had a greater likelihood of reoperation but a lower likelihood of major bleeding.

90 ic valves were associated with lower risk of reoperation but greater risk of bleeding and stroke.

91 ation was found in the data; 90-day rates of reoperations by surgeon ranged from 0% to 100%.

92 ostoperative ileus, sepsis, readmission, and reoperation compared with patients who received neither

93 ment of PLE and arrhythmias and the need for reoperation during long-term follow-up pose significant

94 luding congestive heart failure, paraplegia, reoperation, dyspnea at rest, nongastric band surgery, a

95 40 years regarding survival and the need for reoperations, especially focusing on the results from th

96 pair of a femoral hernia reduces the risk of reoperation for a recurrence compared with open repair.

97 Key adverse events included reoperation for bleeding (14%), driveline infection (10%

98 ys), transient ischemic attack in 1 patient, reoperation for bleeding in 2 patients, and median lengt

99 th increased unplanned cardiac operation and reoperation for bleeding.

100 ative proportion of patients (SE) undergoing reoperation for glaucoma before the 3-year postoperative

101 The relative risk of reoperation for glaucoma in the AGV group was 2.1 times

102 ng because of inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV group (80% of

103 The rate of reoperation for glaucoma was higher following trabeculec

104 educed >/=20% from baseline, IOP >5 mmHg, no reoperation for glaucoma, no loss of light-perception vi

105 an 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vi

106 I and resulted in a greater relative risk of reoperation for glaucoma.

107 The significant multivariable predictors of reoperation for horizontal surgery were adjustable sutur

108 stein's operation but a lower likelihood for reoperation for mesh plug repair.

109 igh rate of device-related complications and reoperation for other causes after ICD implantation.

110 ategy to localize the offending gland before reoperation for persistent or recurrent hyperparathyroid

111 Reoperation for pouch-related problems after LAGB is saf

112 the rates of death or disabling stroke, but reoperation for pump malfunction was less frequent in th

113 pump, primarily because of the lower rate of reoperation for pump malfunction.

114 requiring reoperation or hospitalization and reoperation for reasons other than complications, and to

115 requiring reoperation or hospitalization and reoperation for reasons other than complications.

116 ain Outcomes and Measures: Five-year risk of reoperation for recurrence and 5-year risk of all mesh-r

117 repair was associated with a higher risk of reoperation for recurrence over 5 years compared with op

118 -year progression-free survival was 76%, and reoperation for recurrence was required in 4% of patient

119 Only 9 patients required reoperation for recurrence, with good long-term outcome

120 ry for discrete subaortic stenosis; however, reoperation for recurrent discrete subaortic stenosis is

121 f the patients are off PPIs, and 16% require reoperation for recurrent GERD and/or dysphagia.

122 docrine/exocrine functions and a low rate of reoperation for tumor recurrence.

123 mplications for the majority of defects, and reoperation for valvar problems is common.

124 lysis showed that the adjusted odds ratio of reoperation for women having 1 previous cesarean deliver

125 res were associated with significantly fewer reoperations for horizontal muscle surgery.

126 In this sample, reoperations for macular hole were performed at low rate

127 There were no reoperations for PPM.

128 le sutures tended to be associated with more reoperations for vertical muscle surgery, but this obser

129 us adverse event, with the most common being reoperations (for reasons other than chronic pancreatiti

130 interval from the initial cholecystectomy to reoperation: group A: less than 4 weeks; group B: 4 to 8

131 ents (mean age, 57.5; 76.2% women) requiring reoperation had lower rates of hypertension (64.9% vs 73

132 ss procedure concomitant with a band-related reoperation had more intraoperative complications [risk-

133 Laparoscopic lavage reduced the need for reoperations, had a similar safety profile to the Hartma

134 ant associations between low IOP and time to reoperation (hazard ratio [HR], 0.73; 95% CI, 0.32-1.68)

135 epair was found to result in reduced risk of reoperation (hazard ratio, 0.33; 95% CI, 0.09-0.95) comp

136 Key secondary outcomes were number of reoperations, hospital readmissions, total length of hos

137 dures were associated with increased risk of reoperations (HR: 6.9; p = 0.003), and m-CVG procedures

138 val were: intraoperative blood transfusions, reoperation, human leukocyte antigen mismatch, use of no

139 216 (9.2%), complications in 948 (40%), and reoperation in 167 (7.1%) of 2352 patients.

140 A closure rate of 100 % was achieved with reoperation in 4 eyes.

141 Freedom from need for aortic root reoperation in patients who underwent primarily a compos

142 However, the risk of reoperation in patients with DCIS was 3 times higher tha

143 y was to summarise the risks and benefits of reoperation in patients with epilepsy.

144 There were less reoperations in the mesh plug than in the Lichtenstein's

145 h node harvest, resection margin status, and reoperation incidence were assessed as performance-contr

146 However, 42.5% of the patients needed reoperation, including 10.6% for correction of protein m

147 006 and 2013 identifies gastric band-related reoperations, including device removal, device replaceme

148 the proportion of payments from Medicare for reoperations increased from 16.4% to 77.3% of their annu

149 At 2 years after a glaucoma reoperation, IOP (mean +/- SD) was 15.0 +/- 5.5 mm Hg in

150 Reoperation is associated with a high mortality rate, an

151 tu (DCIS) and to examine whether the risk of reoperation is associated with DCIS or histologic type o

152 Hence, owing to its degenerative character, reoperation is often needed, encompassing an impressive

153 However, reoperations lead to an increased rate of permanent neur

154 ere overall morbidity and mortality, rate of reoperation, length of hospital stay, and rate of stoma

155 ve wound infection, intra-abdominal abscess, reoperation, length of hospital stay, and readmission.

156 ve wound infection, intra-abdominal abscess, reoperation, length of hospital stay, and readmission.

157 included other postoperative complications, reoperations, length of operating time, length of postop

158 Reoperations, length of stay, readmissions, and 90-day m

159 17.4 months) or late (group C: 22.4 months) reoperation (log-rank P = .03).

160 n in risk- and reliability-adjusted rates of reoperation (lower quartile average, 13.3%; upper quarti

161 erence in number of complications treated by reoperation (LSG, n = 9; LRYGB, n = 16, P = 0.15) or num

162 persistent hyperparathyroidism, parathyroid reoperations, morbidity, and mortality were evaluated du

163 resection and stoma formation with risk for reoperations, morbidity, and mortality.

164 Among 1,820 participants, the risk of reoperation/mortality did not increase with greater lymp

165 The main study outcome was reoperation/mortality within 30 days of primary surgery.

166 node metastases did not increase the risk of reoperation/mortality.

167 Rate of device-related reoperation nationally and across individual hospital re

168 r hemorrhage or cardiac tamponade leading to reoperation occurred in 1.4% of the patients in the tran

169 Major hemorrhage leading to reoperation occurred in 1.8% of patients in the aspirin

170 Reoperation occurred in 109 of 826 patients (13.2%) in t

171 Reoperation occurred in 182 of 1229 patients (14.8%) in

172 To describe the rate of device-related reoperations occurring after laparoscopic gastric band s

173 tral reoperation, with a 5-year freedom from reoperation of 97.7% (99.1% simple; 95.7% complex; P=0.1

174 Four patients required reoperation, of which only 1 was for symptomatic recurre

175 Five patients required reoperation on the aortic valve: 2 for endocarditis and

176 procedural major adverse events related to a reoperation or conversion to standard of care.

177 Although many patients needed a reoperation or developed arrhythmias, late mortality was

178 ications per 100 patient-years that required reoperation or hospitalization and 3.9 (CI, 3.8 to 4.0)

179 risk for ICD-related complications requiring reoperation or hospitalization and reoperation for reaso

180 dence of ICD-related complications requiring reoperation or hospitalization and reoperation for reaso

181 st increases the risk of early postoperative reoperation or mortality.

182 Postoperative complications associated with reoperation or vision loss of >2 Snellen lines occurred

183 een the 2 groups with regard to frequency of reoperations or the length of hospital stay, but use of

184 08; 95% confidence interval [CI] 0.96-1.21), reoperation (OR 1.16; 95% CI 0.96-1.40), or readmission

185 ound infection (OR, 0.07; 95% CI, 0.04-0.2), reoperation (OR, 0.5; 95% CI, 0.3-0.9), and mortality (O

186 ve wound infection, intra-abdominal abscess, reoperation, or readmission.

187 ve wound infection, intra-abdominal abscess, reoperation, or readmission.

188 superior long-term survival and freedom from reoperation over single thoracic artery with saphenous v

189 e procedures, 7 endoscopic procedures, and 6 reoperations overall.

190 Ten percent and 5% underwent reoperation (P = 0.11).

191 serious complications (P < 0.001) or perform reoperations (P < 0.001).

192 rative pain scores (P = .034), required more reoperations (P = .050), and had a higher technician wor

193 , APACHE II scores (P = 0.256), incidence of reoperations (P = 1.000), or postoperative bleeding (P =

194 Overall, 10 patients had complications or reoperation per 100 patient-years of follow-up.

195 or hospitalization and 3.9 (CI, 3.8 to 4.0) reoperations per 100 patient-years for reasons other tha

196 ious cesarean delivery increases the risk of reoperation, perioperative and postoperative complicatio

197 Reoperation, perioperative and postoperative complicatio

198 ere 30-day mortality, end-organ dysfunction, reoperation, prolonged hospitalization, nonroutine disch

199 The reported rates of reoperation range from 4% to 60% in short-term studies;

200 sidual grade III HD (15% vs 5%) and a higher reoperation rate (8% vs 4%).

201 For only 1 of the 4 outcomes, ie, reoperation rate (OR 3.73, 95% CI 1.18, 11.82, P = 0.03)

202 ge (18-39 years) was associated with a lower reoperation rate (P </= .02).

203 e (P = .14), complication rate (P = .26), or reoperation rate (P = .17) when surgery was performed by

204 Reoperation rate after wire-guided BCS in patients with

205 To determine the reoperation rate after wire-guided BCS in patients with

206 A lower reoperation rate after wire-guided BCS was found in this

207 The high reoperation rate and incidence of gastroesophageal reflu

208 Patients with BCs had a higher reoperation rate and longer hospital stays.

209 k their intraoperative complication rate and reoperation rate and to compare their surgical technique

210 mpact of the absence of band fixation on the reoperation rate and to identify other risk factors for

211 tion from 20.9% to 15.2% (P = .004), and for reoperation rate at 55 cases, with a reduction from 12.6

212 However, a valid reoperation rate for this procedure needs to be establis

213 nonpalpable breast lesions may decrease the reoperation rate in breast-conserving surgery (BCS) comp

214 ble sutures were not associated with a lower reoperation rate in children.

215 Reoperation rate in the first postoperative year.

216 The reoperation rate increased from 0.91% to 2.73% during th

217 The RD reoperation rate was 13.3%, 12.3%, and 14.5% for PPV, SB

218 igh IOP, and the cumulative de novo glaucoma reoperation rate was 18% in the Ahmed group and 11% in t

219 The reoperation rate was 7.4% for fixed-suture surgeries, 9.

220 in the TVT Study, and the 5-year cumulative reoperation rate was 9% in the tube group and 29% in the

221 The reoperation rate was higher in the soap group than in th

222 The reoperation rate was inversely and nonlinearly related t

223 The reoperation rate was significantly higher in the laparos

224 trol group (n = 19) in morbidity, mortality, reoperation rate, or length of hospital stay.

225 The 5-year heartburn score, dilatation rate, reoperation rate, PPI use, and patient satisfaction were

226 ded chronic pain, sensibility disorders, and reoperation rate.

227 tures were not significantly associated with reoperation rates after vertical muscle surgery (multiva

228 ictors for outcome, including recurrence and reoperation rates during the first postoperative year.

229 decision-maker accepts as the recurrence and reoperation rates for these types of repair, either mesh

230 Reoperation rates tended to be higher with adjustable su

231 tinal reattachment, and second outcomes were reoperation rates, best-corrected visual acuity (BCVA) a

232 ons and four (50%) measured 30 day unplanned reoperation rates.

233 matic reviews shows that difficulties during reoperations, rather than small bowel obstructions, acco

234 ak, pneumonia, nasogastric tube reinsertion, reoperation, readmission, or mortality in the randomized

235 ative imaging, percutaneous drain placement, reoperation, readmission, or quality of life scores.

236 ks, pneumonia, nasogastric tube reinsertion, reoperation, readmissions, and mortality.

237 OR: 8.0, P < 0.001), were at higher risk of reoperations/reinterventions (risk-adjusted OR: 6.0, P <

238 sess the risk for anastomotic complications (reoperation, rescue stoma, revision of an anastomosis, a

239 10 to 1.17; p < 0.001); a steady decrease in reoperation risk until 25 total mitral operations annual

240 se in major bleeding complications requiring reoperation (RR, 0.57; 95% CI, 0.39-0.84; I(2) = 32%; 10

241 Factors concerning recurrence, reoperations, satisfaction, and improved QoL were analyz

242 Adhesiolysis during reoperations seems to impact adhesion-related morbidity

243 An urgent reoperation should be discussed in patients with severe

244 We compared long-term mortality and rates of reoperation, stroke, and bleeding between inverse-probab

245 Main outcome measures included number of reoperations, surgical complications, and follow-up visi

246 de the timing, dosage, and type of treatment.Reoperations tend to be more frequently encountered in t

247 r IOP reduction and a lower rate of glaucoma reoperation than the AGV, but the BGI was associated wit

248 Among presumed reoperations, the rates of reoperation were 4.3% (4.1% a

249 ioprosthetic aortic valve replacement (AVR), reoperation to relieve severe prosthetic aortic stenosis

250 ioprosthetic aortic valve replacement (AVR), reoperation to relieve severe prosthetic aortic stenosis

251 more severe disability) or survival free of reoperation to replace or remove the device at 6 months

252 oint (survival free of a disabling stroke or reoperation to replace the pump for malfunction), driven

253 Reoperations to manage complications were required in 1

254 though the accuracy decreased when comparing reoperations to primary surgeries for the medial (79% to

255 Low IOP after trabeculectomy, reoperation, vision loss, and surgical failure.

256 erative outcomes that were examined included reoperation, vision loss, and surgical failure.

257 The rate of reoperation was 10%, with an overall mortality rate of 2

258 The cumulative rate of reoperation was 14% in the fusion group and 34% in the d

259 Mean overall rate of 90-day reoperation was 30.9% (27 010 of 87 499 patients) and de

260 At 12 years, freedom from reoperation was 57.8+/-7.21% and freedom from recurrence

261 .e., MR >/=2) was 13.3%, incidence of mitral reoperation was 6.9%, and overall mortality was 44.0%.

262 Freedom from reoperation was 69% at 15 years and 63% at 20 years.

263 ergoing gastric band surgery, device-related reoperation was common, costly, and varied widely across

264 The risk of reoperation was correlated to the presence of associated

265 The 15-year cumulative incidence of reoperation was higher in the bioprosthesis group (12.1%

266 The risk of reoperation was higher in women (hazard ratio, 1.95; 95%

267 tic mitral valves; however, the incidence of reoperation was lower in the mechanical prosthesis group

268 Reoperation was performed in 363 patients (2.1%).

269 The incidence of reoperation was significantly higher among recipients of

270 The risk of reoperation was significantly increased in patients with

271 At reoperation, weight was 89.18 +/- 20.51 kg, BMI was 32.2

272 Among presumed reoperations, the rates of reoperation were 4.3% (4.1% after ILM peeling and 5.0% a

273 For vertical surgeries, predictors of reoperation were adjustable-suture use (OR 2.51, P = .10

274 rates and the percentage of cases requiring reoperation were analyzed.

275 complications and complications resulting in reoperation were higher in the Baerveldt Glaucoma Implan

276 Rates of reoperation were highest in women aged 20 to 49 years (3

277 The rates of reoperation were risk adjusted using a multivariable log

278 The rates of reoperation were similar regardless of irrigation pressu

279 The rates for definite reoperations were 1.3% (1.2% after ILM peeling and 1.8%

280 Reoperations were necessary in 1.8% of the cases; the 30

281 The most common reoperations were pacemaker insertion/revision in 212 pa

282 Of the 1072 vertical muscle surgeries, reoperations were performed after 15.2% of adjustable su

283 Of the 4357 horizontal muscle surgeries, reoperations were performed after 5.8% of adjustable sut

284 Reoperations were performed after 8.1% of adjustable sut

285 in 82% of cases, although high morbidity and reoperations were reported.

286 days of operation; major complications (eg, reoperation) were seen in 19 patients (8%).

287 in the database and analyzed for reports of reoperation, which were used as a proxy for recurrence.

288 he procedures, and led in 26% of patients to reoperation with either additional denervation or pallid

289 interval from the initial cholecystectomy to reoperation with overall survival.

290 ents (2 simple, 5 complex), underwent mitral reoperation, with a 5-year freedom from reoperation of 9

291 tmann group (25 of 40; 62.5%) had at least 1 reoperation within 12 months (relative risk reduction, 5

292 The primary end point was reoperation within 12 months after the index surgery for

293 In total, 388 women (5.0%) had a reoperation within 30 days after a hysterectomy.

294 ve heart failure, myocardial infarction, and reoperation within 30 days of surgery.

295 thalmitis, postoperative retinal detachment, reoperation within 30 days, dementia, anxiety disorder,

296 Nearly 1 in 4 women underwent a reoperation within 90 days of BCS across New York State

297 Mitral repair rates, mitral reoperations within 12 months of repair, and survival we

298 the percentage of patients having 1 or more reoperations within 12 months.

299 e eye laterality was not coded) macular hole reoperations within 2, 3, and 12 months were queried.

300 Rate of reoperations within 90 days of the initial BCS procedure